Progress of research on microRNAs with diagnostic value in asbestos exposure: A call for method standardization

BioScience Trends

Volumn 11, Issue 1, 2017, Pages 105-109

  Micolucci, Luigina ^a   Rippo, Maria Rita ^a   Olivieri, Fabiola ^a,b   Procopio, Antonio Domenico ^a,b  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b INRCA   (Italy)

Author keywords

Asbestos; MesomiRs; Mesothelioma; MicroRNA; Molecular pathological epidemiology

Indexed keywords

ASBESTOS; MICRORNA; TUMOR MARKER;

ANALYSIS; ENVIRONMENTAL EXPOSURE; GENETICS; HUMAN; LUNG NEOPLASMS; MESOTHELIOMA; METABOLISM; STANDARD;

ASBESTOS; BIOMARKERS, TUMOR; ENVIRONMENTAL EXPOSURE; HUMANS; LUNG NEOPLASMS; MESOTHELIOMA; MICRORNAS; REFERENCE STANDARDS;

EID: 85014508164     PISSN: 18817815     EISSN: 18817823     Source Type: Journal    
DOI: 10.5582/bst.2016.01249     Document Type: Note

References (25)

1. Frank AL, Joshi TK. The global spread of asbestos. Ann Glob Heal. 2014; 80:257-262.
2. IARC. Arsenic, metals, fibres, and dusts. IARC Monogr Eval Carcinog Risks Hum. 2012; 100:11-465.
3. Norbet C, Joseph A, Rossi SS, Bhalla S, Gutierrez FR. Asbestos-Related Lung Disease: A Pictorial Review. Curr Probl Diagn Radiol. 2015; 44:371-382.
4. Delgermaa V, Takahashi K, Park E-K, Le GV, Hara T, Sorahan T. Global mesothelioma deaths reported to the World Health Organization between 1994 and 2008. Bull World Health Organ. 2011; 89:716-724.
5. Yang H, Testa JR, Carbone M. Mesothelioma epidemiology, carcinogenesis, and pathogenesis. Curr Treat Options Oncol. 2008; 9:147-157.
6. Husain AN, Colby T, Ordonez N, et al. Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med. 2013; 137:647-667.
7. Opitz I. Management of malignant pleural mesothelioma-The European experience. J Thorac Dis. 2014; 6:S238-252.
8. Greillier L, Baas P, Welch JJ, Hasan B, Passioukov A. Biomarkers for malignant pleural mesothelioma: Current status. Mol Diagn Ther. 2008; 12:375-390.
9. Reid G. MicroRNAs in mesothelioma: From tumour suppressors and biomarkers to therapeutic targets. J Thorac Dis. 2015; 7:1031-1040.
10. Shen J, Stass SA, Jiang F. MicroRNAs as potential biomarkers in human solid tumors. Cancer Lett. 2013; 329:125-136.
11. Nair VS, Pritchard CC, Tewari M, Ioannidis JPA. Design and Analysis for Studying microRNAs in Human Disease: A Primer on-Omic Technologies. Am J Epidemiol. 2014; 180:140-152.
12. Turchinovich A, Weiz L, Langheinz A, Burwinkel B. Characterization of extracellular circulating microRNA. Nucleic Acids Res. 2011; 39:7223-7233.
13. Arroyo JD, Chevillet JR, Kroh EM, Ruf IK, Pritchard CC, Gibson DF, Mitchell PS, Bennett CF, Pogosova-Agadjanyan EL, Stirewalt DL, Tait JF, Tewari M. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci U S A. 2011; 108:5003-5008.
14. Vickers KC, Palmisano BT, Shoucri BM, Shamburek RD, Remaley AT. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol. 2011; 13:423-433.
15. Micolucci L, Akhtar MM, Olivieri F, Rippo MR, Procopio AD. Diagnostic value of microRNAs in asbestos exposure and malignant mesothelioma: systematic review and qualitative meta-analysis. Oncotarget. 2016; 7:58606-58637.
16. Ogino S, Lochhead P, Giovannucci E, Meyerhardt JA, Fuchs CS, Chan AT. Discovery of colorectal cancer PIK3CA mutation as potential predictive biomarker: Power and promise of molecular pathological epidemiology. Oncogene. 2014; 33:2949-2955.
17. Hamada T, Keum N, Nishihara R, Ogino S. Molecular pathological epidemiology: new developing frontiers of big data science to study etiologies and pathogenesis. J Gastroenterol. 2016. doi: 10.1007/s00535-016-1272-3.
18. Ogino S, Chan AT, Fuchs CS, Giovannucci E. Molecular pathological epidemiology of colorectal neoplasia: An emerging transdisciplinary and interdisciplinary field. Gut. 2011; 60:397-411.
19. Ogino S, Lochhead P, Chan AT, Nishihara R, Cho E, Wolpin BM, Meyerhardt JA, Meissner A, Schernhammer ES, Fuchs CS, Giovannucci E. Molecular pathological epidemiology of epigenetics: Emerging integrative science to analyze environment, host, and disease. Mod Pathol. 2013; 26:465-484.
20. National Research Council (US) Committee on A Framework for Developing a New Taxonomy of Disease. Toward Precision Medicine. Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease. Washington (DC): National Academies Press (US); 2011. doi: 10.17226/13284.
21. Lu Y-F, Goldstein DB, Angrist M, Cavalleri G. Personalized Medicine and Human Genetic Diversity. Cold Spring Harb Perspect Med. 2014; 4:a008581.
22. Brockmöller J, Tzvetkov M V. Pharmacogenetics: data, concepts and tools to improve drug discovery and drug treatment. Eur J Clin Pharmacol. 2008; 64:133-157.
23. Byron SA, Van Keuren-Jensen KR, Engelthaler DM, Carpten JD, Craig DW. Translating RNA sequencing into clinical diagnostics: opportunities and challenges. Nat Rev Genet. 2016; 17:257-271.
24. Poste G, Compton CC, Barker AD. The national biomarker development alliance: confronting the poor productivity of biomarker research and development. Expert Rev Mol Diagn. 2015; 15:211-218.
25. Barker AD, Compton CC, Poste G. The National Biomarker Development Alliance accelerating the translation of biomarkers to the clinic. Biomark Med. 2014; 8:873-876.